LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study

被引：18
|
作者：
Mato, Anthony R.
Pagel, John M.
Coombs, Catherine C.
Shah, Nirav N.
Lamanna, Nicole
Lech-Maranda, Ewa
Eyre, Toby A.
Woyach, Jennifer A.
Wierda, William G.
Cheah, Chan Yoon
Roeker, Lindsey E.
Patel, Manish R.
Fakhri, Bita
Barve, Minal
Tam, Constantine S.
Lewis, David John
Gerson, James N.
Alencar, Alvaro J.
Taylor, Justin
Abdel-Wahab, Omar
Ghia, Paolo
Schuster, Stephen J.
Chen, Jessica
Nair, Binoj
Tsai, Donald
Ku, Nora C.
Davids, Matthew S.
Brown, Jennifer R.
Jurczak, Wojciech
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-134970
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [41] A Phase (Ph) 2 Study of TL-895, a Highly Selective, Novel Covalent BTK Inhibitor (BTKi), in Patients (pts) with Treatment-Naive (TN) and Relapsed/Refractory (R/R) BTKi-Naive Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
    Byrd, John C.
    Woszczyk, Dariusz
    Illes, Arpad
    Jurczak, Wojciech
    Chraniuk, Dominik
    Giannopoulos, Krzysztof
    Mikhailova, Nataliia
    Illconzai, Peter
    Bhat, Seema A.
    Romanyuk, Nataliya
    Usenko, Ganna
    Kuchkova, Olha
    Chandler, Jason
    Bilotti, Elizabeth
    Shen, Annalise
    Cheung, Jean
    Verstovsek, Srdan
    McGreivy, Jesse
    Rothbaum, Wayne
    Kazmierczak, Maciej
    BLOOD, 2023, 142
  • [42] Interim results from a phase 1/2 precision medicine study of PLX8394-a next generation BRAF inhibitor
    Janku, F.
    Sherman, E. J.
    Parikh, A. R.
    Feun, L. G.
    Tsai, F.
    Allen, E.
    Zhang, C.
    Severson, P.
    Inokuchi, K.
    Walling, J.
    Averbuch, S.
    Tarcic, G.
    Bollag, G.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S2 - S3
  • [43] Trial in Progress: A Phase 1b Study of AS-1763, an Oral, Potent and Selective Noncovalent BTK Inhibitor, in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
    Jain, Nitin
    D'Olimpio, James
    Gillis-Smith, Andew
    Lee, Seung Tae
    Shah, Nirav N.
    Pinilla-Ibarz, Javier
    Coombs, Catherine C.
    Barrientos, Jacqueline C.
    Ma, Shuo
    Sawa, Masaaki
    Miyamoto, Kyoko
    Arimura, Akinori
    Gandhi, Varsha
    Wierda, William G.
    BLOOD, 2023, 142
  • [44] PHASE 1 STUDY OF SINGLE AGENT CC-292, A HIGHLY SELECTIVE BRUTON'S TYROSINE KINASE (BTK) INHIBITOR, IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND B-CELL NON-HODGKIN LYMPHOMA (B-NHL)
    Brown, J.
    Harb, W.
    Sharman, J.
    Hill, B.
    Ma, S.
    Miller, T.
    Schreeder, M.
    Barr, P.
    Foran, J.
    Gabrilove, J.
    Kelly
    Burger, Ja
    Barnett, E.
    Marine, J.
    Nava-Parada, P.
    Azaryan, A.
    Mei, J.
    Kipps, T.
    HAEMATOLOGICA, 2013, 98 : 217 - 217
  • [45] Preliminary results from a phase 1/2 study of INCB054828, a highly selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced malignancies
    Saleh, Mansoor
    Gutierrez, Martin E.
    Subbiah, Vivek
    Smith, David C.
    Asatiani, Ekaterine
    Lihou, Christine F.
    Zhen, Huiling
    Yeleswaram, Swamy
    Ji, Tao
    Nemunaitis, John
    CANCER RESEARCH, 2017, 77
  • [46] Combination Treatment with Sonrotoclax (BGB-11417), a Second-Generation BCL2 Inhibitor, and Zanubrutinib, a Bruton Tyrosine Kinase (BTK) Inhibitor, Is Well Tolerated and Achieves Deep Responses in Patients with Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (TN-CLL/SLL): Data from an Ongoing Phase 1/2 Study
    Tam, Constantine S.
    Anderson, Mary Ann
    Lasica, Masa
    Verner, Emma
    Opat, Stephen S.
    Ma, Shuo
    Weinkove, Robert
    Cordoba, Raul
    Soumerai, Jacob
    Ghia, Paolo
    Leitch, Sophie
    Hilger, James
    Fang, Yiqian
    Simpson, David
    Guo, Haiyi
    Cheah, Chan Yoon
    BLOOD, 2023, 142
  • [47] Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions
    Javle, M.
    Kelley, R. K.
    Roychowdhury, S.
    Weiss, K. H.
    Abou-Alfa, G. K.
    Macarulla, T.
    Sadeghi, S.
    Waldschmidt, D.
    Zhu, A. X.
    Goyal, L.
    Borad, M.
    Yong, W. P.
    Borbath, I.
    El-Khoueiry, A.
    Philip, P.
    Moran, S.
    Ye, Y.
    Ising, M.
    Lewis, N.
    Bekaii-Saab, T.
    ANNALS OF ONCOLOGY, 2018, 29 : 720 - 720
  • [48] Preliminary results from a phase 1/2 study of INCB054828, a highly selective fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced malignancies
    Saleh, Mansoor
    Gutierrez, Martin
    Subbiah, Vivek
    Smith, David C.
    Feliz, Luis
    Zhen, Huiling
    Ji, Tao
    Nemunaitis, John
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [49] A phase 1/2 dose escalation and expansion study of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated non-squamous NSCLC.
    Rashdan, Sawsan
    Williams, Jessica N.
    Currykosky, Penny
    Fattah, Farjana
    Padro, Jonathan
    Wnuk-Lipinska, Katarzyna
    Gausdal, Gro
    Brown, Anthony
    Micklem, David
    Holt, Robert J.
    Lorens, James
    Yule, Murray
    Gerber, David E.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [50] Preliminary results from FLAGSHP-1: A Phase I dose escalation study of ERAS-601, a potent SHP2 inhibitor, in patients with previously treated advanced or metastatic solid tumors
    McKean, M.
    Barve, M.
    Hong, D.
    Parikh, A.
    Rosen, E.
    Yang, J.
    Picard, R.
    Yi, J.
    Brail, L.
    Vecchio, D.
    Meniawy, T.
    John, T.
    Wang, J.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S34 - S34
12345